Navigation Links
Rigel to Present at the Oppenheimer 19th Annual Healthcare Conference
Date:10/29/2008

SOUTH SAN FRANCISCO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, Rigel's executive vice president and chief operating officer, will present a company overview at the Oppenheimer 19th Annual Healthcare Conference on Monday, November 3 at 3:20 p.m. EST at The Waldorf Astoria Hotel in New York City.

To access the live audio webcast or the subsequent archived recording, log on to http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Contact: Ryan Maynard

Phone: 650.624.1284

Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Rigel to Webcast Investor Update on October 27, 2008
2. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
3. Rigel to Present at Collins Stewart Growth Conference
4. Rigel Announces First Quarter 2008 Financial Results
5. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
6. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
7. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
8. Rigel Announces Offering of 4,000,000 Shares of Common Stock
9. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
10. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
11. Rigel Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... The Behavioral Health Center of Excellence ... organization as a top behavioral service provider in the country. The award celebrates ... satisfaction and qualifications, and consumer satisfaction. These areas are measured via a wide-ranging ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation involving human stem ... largely due to its potential for revolutionizing human disease treatment. There are multiple ... pluripotent stem cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, ...
(Date:12/6/2016)... ... 06, 2016 , ... METTLER TOLEDO has launched its online ... white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user ... documents, webinars and videos available online, visit the METTLER TOLEDO Expertise Library ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... B.C., Canada (PRWEB) , ... December 06, 2016 ... ... (STC) announce the availability of the newly updated International Audit Protocol Consortium (IAPC) ... use IAPC EHS audit protocols to understand the scope of their EHS regulatory ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016  Balloon catheter is ... which is inserted into the femoral artery in the ... arm to treat constricted blood vessels. These products are ... to atherosclerosis – deposition of lipid substances in the ... catheter market is projected to expand at a CAGR ...
(Date:12/5/2016)... , Dec. 5, 2016 Spain Glaucoma Surgery ... new report, "Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices market. The report provides value, in millions ... (USD) within market segements - Canaloplasty Micro Catheters and ... shares and distribution shares data for each of these ...
(Date:12/5/2016)... 5, 2016  Cornerstone Pharmaceuticals, Inc., a privately ... from two Phase I trials evaluating its lead ... annual meeting of the American Society of Hematology ... . The two datasets show encouraging efficacy and ... (AML) and T-cell non-Hodgkin,s lymphoma (T-cell NHL), respectively, ...
Breaking Medicine Technology: